Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass

Abstract

Osteoporosis, a prevalent age-related disease, is characterized by impaired bone formation and an increased risk of fractures. Current anabolic treatments primarily rely on biologics, which are costly and require inconvenient administration. Identifying regulators of osteoblastogenesis that are amenable to small-molecule targeting is essential for developing more accessible therapies. Through an unbiased kinome-wide RNAi screen in primary murine calvarial osteoblasts, we identified the AXL receptor tyrosine kinase (Axl) as a negative regulator of osteoblast differentiation. Axl is most highly expressed in undifferentiated and early differentiated osteoblasts, with a rapid decline in expression during osteoblast maturation. siRNA-mediated knockdown of Axl or pharmacological inhibition with the small molecule BGB324 significantly enhanced osteoblast differentiation and mineralization in vitro. In mice, BGB324 treatment significantly increased bone mass by promoting bone formation. Mechanistically, Axl knockdown or inhibition upregulated interferon-stimulated gene 15 (Isg15), while Isg15 knockdown impaired osteoblast differentiation and enhanced Erk phosphorylation, leading to increased expression of osteoblast-specific genes. Consistently, double knockdown experiments demonstrated that simultaneous loss of Axl with either Isg15 or Mapk1, but not other interferon-related genes, reversed the Axl knockdown-induced increase in osteoblast differentiation, reinforcing their mechanistic involvement. Collectively, our study identifies Axl as a promising therapeutic target for osteoporosis and other bone-related disorders.

References

[1] Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J. Steroid Biochem. Mol. Biol., 2014, 142: 155-170

[2] Bonnick SL. Osteoporosis in men and women. Clin. Cornerstone, 2006, 8: 28-39

[3] Seeman E, Delmas PD. Bone quality–the material and structural basis of bone strength and fragility. N. Engl. J. Med., 2006, 354: 2250-2261

[4] Salari N, et al. . The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J. Orthop. Surg. Res., 2021, 16: 609

[5] Salari N, et al. . Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J. Orthop. Surg. Res., 2021, 16: 669

[6] Hernlund E, et al. . Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos., 2013, 8 136

[7] Feng JN, et al. . Global burden of hip fracture: the Global Burden of Disease Study. Osteoporos. Int., 2024, 35: 41-52

[8] Liang B, Burley G, Lin S, Shi YC. Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell. Mol. Biol. Lett., 2022, 27: 72

[9] Bolamperti S, Villa I, Rubinacci A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Res., 2022, 10: 48

[10] Kim, J. M., Lin, C., Stavre, Z., Greenblatt, M. B. & Shim, J. H. Osteoblast-osteoclast communication and bone homeostasis. Cells9, 2073 (2020).

[11] Pignolo RJ, Law SF, Chandra A. Bone aging, cellular senescence, and osteoporosis. JBMR Plus, 2021, 5 e10488

[12] Cheng, C. H., Chen, L. R. & Chen, K. H. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int. J. Mol. Sci.23, 1376 (2022).

[13] Fan H, et al. . Recent advances in senescence-associated secretory phenotype and osteoporosis. Heliyon, 2024, 10 e25538

[14] Mi B, et al. . Ageing-related bone and immunity changes: insights into the complex interplay between the skeleton and the immune system. Bone Res., 2024, 12: 42

[15] Langdahl BL. Overview of treatment approaches to osteoporosis. Br. J. Pharmacol., 2021, 178: 1891-1906

[16] Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv. Ther., 2022, 39: 58-74

[17] Xu H, et al. . Targeting strategies for bone diseases: signaling pathways and clinical studies. Signal Transduct. Target. Ther., 2023, 8: 202

[18] Rachner TD, Hofbauer LC, Göbel A, Tsourdi E. Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. J. Mol. Endocrinol., 2019, 62: R145-r154

[19] Cosman F, et al. . Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med., 2016, 375: 1532-1543

[20] Eastell R, et al. . Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J. Clin. Endocrinol. Metab., 2019, 104: 1595-1622

[21] Bandeira L, Lewiecki EM. Anabolic therapy for osteoporosis: update on efficacy and safety. Arch. Endocrinol. Metab., 2022, 66: 707-716

[22] Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell, 2010, 141: 1117-1134

[23] Tomuleasa C, et al. . Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct. Target. Ther., 2024, 9: 201

[24] Engelmann J, et al. . Regulation of bone homeostasis by MERTK and TYRO3. Nat. Commun., 2022, 13 7689

[25] Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. Curr. Opin. Immunol., 2010, 22: 740-746

[26] Vago JP, Amaral FA, van de Loo FAJ. Resolving inflammation by TAM receptor activation. Pharmacol. Ther., 2021, 227 107893

[27] Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res., 2008, 100: 35-83

[28] Yadav M, et al. . AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduct. Target. Ther., 2025, 10: 37

[29] Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. TAM receptor signaling in immune homeostasis. Annu. Rev. Immunol., 2015, 33: 355-391

[30] Pirson S, et al. . AXL promotes lymphangiogenesis by amplifying VEGF-C-mediated AKT pathway. Cell. Mol. Life Sci. CMLS, 2025, 82: 95

[31] Ahmad M, et al. . Inhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing. Bone Res., 2022, 10: 33

[32] Zhang G, Wang M, Zhao H, Cui W. Function of Axl receptor tyrosine kinase in non-small cell lung cancer. Oncol. Lett., 2018, 15: 2726-2734

[33] Fujimori T, et al. . The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. Mucosal Immunol., 2015, 8: 1021-1030

[34] Batchu SN, et al. . Innate immune cells are regulated by Axl in hypertensive kidney. Am. J. Pathol., 2018, 188: 1794-1806

[35] Tutusaus A, Morales A, García de Frutos P, Marí M. GAS6/TAM axis as therapeutic target in liver diseases. Semin. Liver Dis., 2024, 44: 99-114

[36] Richardson L, et al. . EMAGE mouse embryo spatial gene expression database: 2014 update. Nucleic Acids Res., 2014, 42: D835-D844

[37] Sikora M, Śmieszek A, Marycz K. Bone marrow stromal cells (BMSCs CD45(-) /CD44(+) /CD73(+) /CD90(+)) isolated from osteoporotic mice SAM/P6 as a novel model for osteoporosis investigation. J. Cell Mol. Med., 2021, 25: 6634-6651

[38] Picke, A. K. et al. Thy-1 (CD90) promotes bone formation and protects against obesity. Sci. Transl. Med.10, eaao6806 (2018).

[39] Saalbach A, Anderegg U. Thy-1: more than a marker for mesenchymal stromal cells. FASEB J., 2019, 33: 6689-6696

[40] Ludwig KF, et al. . Small-molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer. Cancer Res., 2018, 78: 246-255

[41] Bhalla S, et al. . Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer, 2023, 182 107291

[42] Liu Z, et al. . Recent discovery and development of AXL inhibitors as antitumor agents. Eur. J. Med. Chem., 2024, 272 116475

[43] Vouri M, An Q, Birt M, Pilkington GJ, Hafizi S. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. Oncotarget, 2015, 6: 16183-16197

[44] Straume O, Schuster C, Gausdal G, Lorens J, Gjertsen BT. A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol., 2018, 36: 9548-9548

[45] Holland SJ, et al. . R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res., 2010, 70: 1544-1554

[46] Freed SM, et al. . MEK/ERK MAP kinase limits poly I:C-induced antiviral gene expression in RAW264.7 macrophages by reducing interferon-beta expression. FEBS Lett., 2021, 595: 2665-2674

[47] Guo G, et al. . A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nat. Neurosci., 2017, 20: 1074-1084

[48] Matsushita T, et al. . Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell Biol., 2009, 29: 5843-5857

[49] Kim, J. M. et al. The ERK MAPK Pathway Is Essential for Skeletal Development and Homeostasis. Int. J. Mol. Sci.20, 1803 (2019).

[50] Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet, 2019, 393: 364-376

[51] Neer RM, et al. . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344: 1434-1441

[52] Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat. Rev. Immunol., 2008, 8: 327-336

[53] Zagorska A, Traves PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. Nat. Immunol., 2014, 15: 920-928

[54] Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J. Immunol., 2007, 178: 5635-5642

[55] Okamoto H, et al. . Involvement of microRNAs in regulation of osteoblastic differentiation in mouse induced pluripotent stem cells. PLoS ONE, 2012, 7: e43800

[56] Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat. Rev. Mol. Cell Biol., 2012, 13: 27-38

[57] Hojo, H. & Ohba, S. Sp7 action in the skeleton: its mode of action, functions, and relevance to skeletal diseases. Int. J. Mol. Sci.23, 5647 (2022).

[58] Hojo H, Chung UI, Ohba S. Identification of the gene-regulatory landscape in skeletal development and potential links to skeletal regeneration. Regen. Ther., 2017, 6: 100-107

[59] Bhalla S, Gerber DE. AXL inhibitors: status of clinical development. Curr. Oncol. Rep., 2023, 25: 521-529

[60] Tu X, et al. . Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc. Natl. Acad. Sci. USA, 2015, 112: E478-E486

[61] Bonewald LF. The amazing osteocyte. J. Bone Miner. Res., 2011, 26: 229-238

[62] Dallas SL, Bonewald LF. Dynamics of the transition from osteoblast to osteocyte. Ann. N. Y Acad. Sci., 2010, 1192: 437-443

[63] Hung CN, et al. . AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Rep., 2023, 42 113067

[64] Perng YC, Lenschow DJ. ISG15 in antiviral immunity and beyond. Nat. Rev. Microbiol., 2018, 16: 423-439

[65] Álvarez, E. et al. Unveiling the multifaceted roles of ISG15: from immunomodulation to therapeutic frontiers. Vaccines12, 153 (2024).

[66] Kang JA, Kim YJ, Jeon YJ. The diverse repertoire of ISG15: more intricate than initially thought. Exp. Mol. Med., 2022, 54: 1779-1792

[67] Albers J, et al. . Control of bone formation by the serpentine receptor Frizzled-9. J. Cell Biol., 2011, 192: 1057-1072

[68] Strange, D. P. et al. Axl promotes Zika virus entry and modulates the antiviral state of human Sertoli cells. mBiohttps://doi.org/10.1128/mBio.01372-19 (2019).

[69] Zhang D, et al. . Axl mediates resistance to respiratory syncytial virus infection independent of cell attachment. Am. J. Respir. Cell Mol. Biol., 2022, 67: 227-240

[70] Read SA, et al. . Hepatitis C virus driven AXL expression suppresses the hepatic type I interferon response. PLoS ONE, 2015, 10: e0136227

[71] Sainz BJr., Martín B, Tatari M, Heeschen C, Guerra S. ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res., 2014, 74: 7309-7320

[72] Nguyen HM, et al. . Interferon stimulated gene 15 (ISG15) in cancer: an update. Cancer Lett., 2023, 556 216080

[73] Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell, 2007, 131: 1124-1136

[74] Schmid, E. T. et al. AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. eLife5, e12414 (2016).

[75] Zhao B, et al. . Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med., 2009, 15: 1066-1071

[76] Engelmann, J., Ragipoglu, D., Ben-Batalla, I. & Loges, S. The role of TAM receptors in bone. Int. J. Mol. Sci.25, 233 (2023).

[77] Pata, M. et al. Vitamin K-dependent carboxylation in osteoblasts regulates bone resorption through GAS6. Preprint at bioRxivhttps://doi.org/10.1101/2025.09.08.673085 (2025).

[78] Burstyn-Cohen T. TAM receptor signaling in development. Int. J. Dev. Biol., 2017, 61: 215-224

[79] Tanaka M, Dykes SS, Siemann DW. Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling. Clin. Exp. Metastasis, 2021, 38: 321-335

[80] Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br. J. Cancer, 2017, 116: 415-423

[81] Van Beusecum JP, et al. . Growth arrest specific-6 and Axl coordinate inflammation and hypertension. Circ. Res., 2021, 129: 975-991

[82] Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev., 2008, 22: 1276-1312

[83] Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol., 2015, 4: 215-266

[84] Epsley S, et al. . The effect of inflammation on bone. Front. Physiol., 2020, 11 511799

[85] Newman H, Shih YV, Varghese S. Resolution of inflammation in bone regeneration: From understandings to therapeutic applications. Biomaterials, 2021, 277 121114

[86] Chiu CL, et al. . Targeting AXL inhibits the growth and metastasis of prostate cancer in bone. Clin. Cancer Res., 2025, 31: 1346-1358

[87] Percie du Sert, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J. Physiol.598, 3793–3801 (2020).

[88] Erdmann R, et al. . BGB324 represents an Axl and BCR-ABL1 inhibitor with activity in the T315I mutant. Blood, 2014, 124: 4512

[89] Ahmad M, et al. . Cell-based RNAi screening and high-content analysis in primary calvarian osteoblasts applied to identification of osteoblast differentiation regulators. Sci. Rep., 2018, 8 14045

[90] Bakker AD, Klein-Nulend J. Osteoblast isolation from murine calvaria and long bones. Methods Mol. Biol., 2012, 816: 19-29

[91] Ahmad M, et al. . Mechanical induction of osteoanabolic Wnt1 promotes osteoblast differentiation via Plat. FASEB J., 2024, 38 e23489

[92] Ahmad M, et al. . Downregulation of the autism spectrum disorder gene Shank2 decreases bone mass in male mice. JBMR Plus, 2023, 7 e10711

[93] Marini F, Binder H. pcaExplorer: an R/Bioconductor package for interacting with RNA-seq principal components. BMC Bioinform., 2019, 20 331

[94] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15 550

[95] Zhou Y, et al. . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun., 2019, 10 1523

[96] Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods, 2012, 9: 671-675

[97] Bouxsein ML, et al. . Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res., 2010, 25: 1468-1486

[98] Liu P, et al. . Loss of menin in osteoblast lineage affects osteocyte-osteoclast crosstalk causing osteoporosis. Cell Death Differ., 2017, 24: 672-682

[99] Wang F, et al. . RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn., 2012, 14: 22-29

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation)(Project No. 251293561)

Federal Ministry of Research, Technology and Space (Bundesministerium für Forschung, Technologie und Raumfahrt, BMFTR) as part of the German Center for Child and Adolescent Health (DZKJ) under the funding code 01GL2407A.

Mubashir Ahmad was supported by a Baustein grant (L.SBN.0224) from the Medical Faculty of Ulm University.

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)(BMBF-01ED2301)

RIGHTS & PERMISSIONS

The Author(s)